Evidence map›Paper›PMID 34290992›Full record

ArticleFrontiers in cellular and infection microbiology2021

Increased PD-1 Level in Severe Cervical Injury Is Associated With the Rare Programmed Cell Death 1 (

Mauro César da Silva, Fernanda Silva Medeiros, Neila Caroline Henrique da Silva, Larissa Albuquerque Paiva, Fabiana Oliveira Dos Santos Gomes, Matheus Costa E Silva, Thailany Thays Gomes, Christina Alves Peixoto, Maria Carolina Valença Rygaard, Maria Luiza Bezerra Menezes and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Mauro César da SilvaLaboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Fernanda Silva MedeirosLaboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Neila Caroline Henrique da SilvaLaboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Larissa Albuquerque PaivaGetúlio Vargas Hospital, Pernambuco Health Department, Recife, Brazil.
Fabiana Oliveira Dos Santos GomesLaboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Matheus Costa E SilvaClinical Immunology Division, Department of Medicine, School of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil.
Thailany Thays GomesLaboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Christina Alves PeixotoLaboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Maria Carolina Valença RygaardLaboratory of Molecular Biology, IMIP Hospital, Pediatric Oncology Service, Recife, Brazil.
Maria Luiza Bezerra MenezesDepartment of Maternal and Child, Faculty of Medical Sciences, University of Pernambuco, Recife, Brazil.
Stefan WelkovicIntegrated Health Center Amaury de Medeiros (CISAM), University of Pernambuco, Recife, Brazil.
Eduardo Antônio DonadiClinical Immunology Division, Department of Medicine, School of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil.
Norma Lucena-SilvaLaboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Fundação Oswaldo Cruz · BRInstituto de Medicina Integral Professor Fernando Figueira · BRUniversidade de Pernambuco · BRUniversidade de São Paulo · BRFundação Getulio Vargas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high-risk oncogenic human papillomavirus (HPV) has developed mechanisms for evasion of the immune system, favoring the persistence of the infection. The chronic inflammation further contributes to the progression of tissue injury to cervical cancer. The programmed cell death protein (PD-1) after contacting with its ligands (PD-L1 and PD-L2) exerts an inhibitory effect on the cellular immune response, maintaining the balance between activation, tolerance, and immune cell-dependent lesion. We evaluated 295 patients exhibiting or not HPV infection, stratified according to the location (injured and adjacent non-injured areas) and severity of the lesion (benign, pre-malignant lesions). Additionally, we investigated the role of the promoter region

Indexed as

Papillomavirus InfectionsProgrammed Cell Death 1 ReceptorUterine Cervical DysplasiaAllelesApoptosisFemaleHumansPDCD1 protein, humanProgrammed Cell Death 1 ReceptorcancerCINHPVinflammationPD-1polymorphism

Identifiers

PMID34290992
PMCPMC8288189
OpenAlexW3185537879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.